Blog Archives

Myeloma CURE Through Targeted Therapy! It Is What Our Body Would Do If It Could! ADC (Antibody Drug Conjugates)

10/19/2018

Myeloma - The Enemy

As I look over the myeloma treatment landscape, it is almost impossible not to be overly enthusiastic. In the beginning there was just Alkylating agents, steroids and Stem Cell Transplant. Then the novel drugs made the scene with Thalamid, Velcade, followed by second generation proteasome inhibitors and imids, and finally monoclonal antibodies and CAR T(single target). Now we are on the cusp of the last stages of development of many other new classes of drugs and treatments. One or a combination of which, will be the silver bullet for those with late stage or high risk myeloma. A recent publication from Australia has studied more than 2 million cancer patients and have concluded the reduction in T cell production in the thymus gland reduces with age. CLICK HERE! It is believed the reduced immune system status (reduced T cells) is no longer robust enough to keep the damage from carcinogens at bay. It is therefore logical to bring the immune system back to a level where it can once again obtain the upper hand on the cancer! Some of the newer techniques to achieve this immune system improvement are Bispecific CAR T, ADC(Antibody Drug Conjugates), AWC(Antibody Warhead Conjugates), MILS(Marrow Infiltrating Lymphocytes), and so very many more.

In a recent Cure Talks broadcast Dr. June, the father of CAR T, said it was no longer a matter of if, but a matter of when we will find a cure for myeloma and most cancers. His point was with CAR T, it was just a matter of finding the right target antigen or combination of antigens on the surface of the cancerous cell and this would be the method to cure. For myeloma he identified two antigens and is now conducting a trial for bi specific CAR T cells which have two targets. So if some of the cells do not express one antigen, then it likely expresses the other and is still destroyed. Combinations of CAR T expressing BCMA, CD19, and CD38 are already in clinical trials or under consideration. In addition there is work on many bispecific and even trispecific combinations. CAR T has great potential with combination targets.

Another recent discovery has been the use of monoclonal antibodies. Daratumumab has been an exciting new treatment with a single agent overall response rate of 29%. However Glaxo Smith Kline has taken this one step further by attaching a toxin to their BCMA antibody. This is called an ADC(Antibody Drug Conjugate). This seems like a new development, however this concept was proposed in 1913 by German physician and scientist Paul Ehrlich of the selective delivery of toxic agents to target cells causing disease. An example of this concept for myeloma is the new drug GSK2857916 which now is in clinical trial. The overall response rate for this drug as single agent was 60% or twice that of Daratumumab. Not to be left behind Daratumumab has been turned into a AWC(Anitbody Warhead Conjugate) by the biotech company Actinium Pharmaceuticals, Inc.(ATNM) This AWC showed a 10 fold improvement in myeloma cell death in vivo vs. Darzalex alone. Finally, Takeda has a new CD38 antibody called TAK-079 and they are partnering with the biotech Molecular Templates(MTEM) to manufacture what they call a ETB(Engineered Toxin Bodies)

ADC, AWC, & ETB all have one thing in common. They have a Payload linked to the Antibody with a Linker. The Antibody attaches to the cancer cell and the Payload and Antibody kills the cancer.

When we hear of drugs having twice to 10 times the killing power of any other single agent activity yet tested, we must be on the cusp of CURE.

If age related reduction in immune system function is a key to myeloma progression, then improvements in T cell function seems like a logical approach. In line with this premise is an interesting development at Johns Hopkins, spearheaded by the Dr. Ivan Borrello. It is the use of MIL's. MIL's (marrow infiltrating lymphocytes) are T cells which are in the bone marrow, and the body has mobilized them to fight the myeloma. It is therefore thought expanding them and reentering a new larger T cell army to turn the tide back to the patient. Dr. Borello states: ”The concept is that the bone marrow, in addition to being the site of the tumor is also a very unique immune site where it is a reservoir of memory antigen experienced T cells."

Good luck and may God Bless your Cancer Journey. For more information on multiple myeloma survival rates and treatments CLICK HERE and you can follow me on twitter at: https://twitter.com/grpetersen1

3 Comments

The Proof Capital Vultures Are Destroying Baby Bio Tech Companies Before They Have Time To Create New Drugs!

10/8/2018

0 Comments

The Budget for the entire NCI (National Cancer Institute) is $5.74 billion. This seems like a lot of money, but compared to the 609,000 patients who die of cancer each year and the estimated cost to bring one drug to market of as much as $2.5 billion, maybe not so much! As noted in my last post, small, micro, and nano tech companies are the ones who initiate the development of many of the new drugs. Unfortunately these small vulnerable firms are under attack by ruthless Capital Vultures who attack and overpower these small company stocks through illegal MANIPULATION of their stock. These Capital Vampires make huge profits at the expense of the small company's ability to stay in business by driving the stock price down and making it difficult to stay in business. The greatest catastrophe is the millions of lives lost because cancer patients will never benefit from these potentially life saving cancer drugs.

CAPITAL VULTURES

The method used to manipulate stocks is called the short sale. It is a concept where you sell shares of a stock of a company you do not own. A broker will loan you the shares at a small cost and let you replace them in the future.   Either the broker must own the shares or have approval from owners of the shares. I have owned stock most of my life, yet have never been asked to allow them to be shorted, and why would anybody loan out their shares when the short sellers objective is to drive down the stocks value? The very concept of selling something you do not own, just does not ring true!

Baby bio techs usually start out as an idea funded by grants to Universities, and once they prove to have potential, go public and sell stock to continue the funding for the years it takes to get a drug from the lab to the clinic. They often do not make money for years until they show excellent results in Phase 2 and Phase 3 clinical trials. At that point they are usually purchased by a large bio tech who will spend the billions to bring it to market.

So where is this evidence? Stocks have risk and baby bio tech firms have more than most firms due to their very nature As the saying goes, one expects more reward if you take on risk. This should mean baby bio-techs on average should have a higher return because of their higher risk!   In the last 5 years the Dow Jones Industrial average is up more than 75%, so we should expect the group of micro tech companies ( those with a market value of between $50 and $300 million) to outperform the Dow and S& P. Returns might be as much as twice that of the Dow, because the Dow has a very small risk compared to the micro bio-techs.

The return for the average of all the micro tech cancer firms listed at: http://investsnips.com/list-of-publicly-traded-micro-cap-diversified-biotechnology-and-pharmaceutical-companies/ is not positive at all, nor even half of that for the Dow, but it is a return of -55%. Today's Market Value is a total of $12.3 billion for all of the micro bio techs listed and if the stocks had lost 55% of their value the Market Value should have been $27.2 billion without these Capital Attacks. This is a loss of value of $14.9 billion or 2.6 times greater than the entire NCI budget. Just think how they would have done if the companies would have grown another 75% just like the Dow. Unlike most other non bio micro cap stocks, these companies if they fail result in LIVES LOST, and not just a bankruptcy.

Elon Musk says short sellers are attacking his stock, and even though the Tesla Market Value is $43.1 Billion, it could be considered stock manipulation by short sellers if thery were also providing misinformation to drive the stock lower. Greenlight Capital and Vilas Capital Management are both major short sellers of Tesla stock and will loose billions if the stock goes up. They have been part of what many believe is a smear campaign of Tesla to drive the stock price lower. Articles CLICK HERE and HERE. If the allegations by short sellers that 1)Tesla will lose more money on every new Model 3 sold or 2)Tesla is another Lehman Brothers are proved false, these short sellers should be prosecuted for criminal stock manipulation.

I bring up this example to explain how short sellers can impact companies like Tesla with a market value of $43.1 billion, just think how devastating a similar attack can impact a company with a market value of $50 million. This is not a fair fight, but more like a slaughter. The system is broken and must be changed to allow new cancer drugs to make it from the lab to the clinic. Short selling activity does not improve market liquidity, it just provides a cheap weapon for the Capital Vultures to crush the small and most vulnerable bio tech cancer companies. How many Cancer Patients will these Capital Vultures KILL?

I have entered complaints to the SEC, FBI, and sent my feelings to many federal senators and representatives and have not heard back from any of them. There have been hundreds of complaints to the SEC, but the issue continues and now is worse because it means peoples lives. Cancer will strike half of all people so if you are in a family of 4, 2 will get cancer.   Legislators are generally older and cancer generally affects these people with a much higher frequency, so do something to save yourselves and your family. Stop this madness!

0 Comments

Myeloma CURE Through Targeted Therapy! It Is What Our Body Would Do If It Could! ADC (Antibody Drug Conjugates)

ADC, AWC, & ETB all have one thing in common. They have a Payload linked to the Antibody with a Linker. The Antibody attaches to the cancer cell and the Payload and Antibody kills the cancer.

The Proof Capital Vultures Are Destroying Baby Bio Tech Companies Before They Have Time To Create New Drugs!

Author

Categories

Archives